<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS Negl Trop Dis</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosntds</journal-id>
<journal-title-group>
<journal-title>PLOS Neglected Tropical Diseases</journal-title>
</journal-title-group>
<issn pub-type="epub">1935-2735</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pntd.0007057</article-id>
<article-id pub-id-type="publisher-id">PNTD-D-18-00798</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Infectious diseases</subject><subj-group><subject>Infectious disease control</subject><subj-group><subject>Vaccines</subject><subj-group><subject>Cholera vaccines</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical microbiology</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Bacterial pathogens</subject><subj-group><subject>Vibrio cholerae</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pathology and laboratory medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Bacterial pathogens</subject><subj-group><subject>Vibrio cholerae</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Bacteria</subject><subj-group><subject>Vibrio</subject><subj-group><subject>Vibrio cholerae</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Immunologic techniques</subject><subj-group><subject>Immunoassays</subject><subj-group><subject>Enzyme-linked immunoassays</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Immune physiology</subject><subj-group><subject>Antibodies</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Immune physiology</subject><subj-group><subject>Antibodies</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune system proteins</subject><subj-group><subject>Antibodies</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune system proteins</subject><subj-group><subject>Antibodies</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Immune system proteins</subject><subj-group><subject>Antibodies</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune response</subject><subj-group><subject>Antibody response</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune response</subject><subj-group><subject>Antibody response</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Cell biology</subject><subj-group><subject>Cellular types</subject><subj-group><subject>Animal cells</subject><subj-group><subject>Immune cells</subject><subj-group><subject>Antibody-producing cells</subject><subj-group><subject>B cells</subject><subj-group><subject>Memory B cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune cells</subject><subj-group><subject>Antibody-producing cells</subject><subj-group><subject>B cells</subject><subj-group><subject>Memory B cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune cells</subject><subj-group><subject>Antibody-producing cells</subject><subj-group><subject>B cells</subject><subj-group><subject>Memory B cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Cell biology</subject><subj-group><subject>Cellular types</subject><subj-group><subject>Animal cells</subject><subj-group><subject>Blood cells</subject><subj-group><subject>White blood cells</subject><subj-group><subject>B cells</subject><subj-group><subject>Memory B cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Cell biology</subject><subj-group><subject>Cellular types</subject><subj-group><subject>Animal cells</subject><subj-group><subject>Immune cells</subject><subj-group><subject>White blood cells</subject><subj-group><subject>B cells</subject><subj-group><subject>Memory B cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune cells</subject><subj-group><subject>White blood cells</subject><subj-group><subject>B cells</subject><subj-group><subject>Memory B cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune cells</subject><subj-group><subject>White blood cells</subject><subj-group><subject>B cells</subject><subj-group><subject>Memory B cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune response</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune response</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Infectious diseases</subject><subj-group><subject>Infectious disease control</subject><subj-group><subject>Vaccines</subject></subj-group></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>Bivalent oral cholera vaccination induces a memory B cell response to the <italic>V. cholerae</italic> O1-polysaccharide antigen in Haitian adults</article-title>
<alt-title alt-title-type="running-head">Oral <italic>cholera vaccine</italic> and memory B cells</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Falkard</surname>
<given-names>Brie</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Charles</surname>
<given-names>Richelle C.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-5371-1354</contrib-id>
<name name-style="western">
<surname>Matias</surname>
<given-names>Wilfredo R.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Mayo-Smith</surname>
<given-names>Leslie M.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Jerome</surname>
<given-names>J. Gregory</given-names>
</name>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<xref ref-type="aff" rid="aff004"><sup>4</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-9116-6916</contrib-id>
<name name-style="western">
<surname>Offord</surname>
<given-names>Evan S.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Xu</surname>
<given-names>Peng</given-names>
</name>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff005"><sup>5</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Kováč</surname>
<given-names>Pavol</given-names>
</name>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff005"><sup>5</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Ryan</surname>
<given-names>Edward T.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff006"><sup>6</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Qadri</surname>
<given-names>Firdausi</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff007"><sup>7</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Franke</surname>
<given-names>Molly F.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Funding acquisition</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff008"><sup>8</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Ivers</surname>
<given-names>Louise C.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Funding acquisition</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff004"><sup>4</sup></xref>
<xref ref-type="aff" rid="aff008"><sup>8</sup></xref>
<xref ref-type="aff" rid="aff009"><sup>9</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<name name-style="western">
<surname>Harris</surname>
<given-names>Jason B.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Funding acquisition</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff010"><sup>10</sup></xref>
<xref ref-type="aff" rid="aff011"><sup>11</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, United States of America</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>Department of Medicine, Harvard Medical School, Boston, MA, United States of America</addr-line></aff>
<aff id="aff003"><label>3</label> <addr-line>Department of Medicine, Brigham and Women’s Hospital, Boston, MA, United States of America</addr-line></aff>
<aff id="aff004"><label>4</label> <addr-line>Partners In Health, Boston, MA, United States of America</addr-line></aff>
<aff id="aff005"><label>5</label> <addr-line>NIDDK, LBC, Section on Carbohydrates, National Institutes of Health, Bethesda, MD, United States of America</addr-line></aff>
<aff id="aff006"><label>6</label> <addr-line>Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, United States of America</addr-line></aff>
<aff id="aff007"><label>7</label> <addr-line>Infectious Diseases Division, icddr,b, (International Centre for Diarrhoeal Disease Research, Bangladesh), Dhaka, Bangladesh</addr-line></aff>
<aff id="aff008"><label>8</label> <addr-line>Department of Global Health &amp; Social Medicine, Harvard Medical School, Boston, MA, United States of America</addr-line></aff>
<aff id="aff009"><label>9</label> <addr-line>Center for Global Health, Massachusetts General Hospital, Boston, MA, United States of America</addr-line></aff>
<aff id="aff010"><label>10</label> <addr-line>Division of Pediatric Global Health, Massachusetts General Hospital, Boston, MA, United States of America</addr-line></aff>
<aff id="aff011"><label>11</label> <addr-line>Department of Pediatrics, Harvard Medical School, Boston, MA, United States of America</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Quilici</surname>
<given-names>Marie-Laure</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>Institut Pasteur, FRANCE</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>The authors have declared that no competing interests exist.</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">jbharris@partners.org</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>31</day>
<month>1</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<month>1</month>
<year>2019</year>
</pub-date>
<volume>13</volume>
<issue>1</issue>
<elocation-id>e0007057</elocation-id>
<history>
<date date-type="received">
<day>18</day>
<month>5</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>5</day>
<month>12</month>
<year>2018</year>
</date>
</history>
<permissions>
<license xlink:href="https://creativecommons.org/publicdomain/zero/1.0/" xlink:type="simple">
<license-p>This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/" xlink:type="simple">Creative Commons CC0</ext-link> public domain dedication.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pntd.0007057"/>
<abstract>
<p>The bivalent killed whole-cell oral cholera vaccine (BivWC) is being increasingly used to prevent cholera. The presence of O-antigen-specific memory B cells (MBC) has been associated with protective immunity against cholera, yet MBC responses have not been evaluated after BivWC vaccination. To address this knowledge gap, we measured <italic>V</italic>. <italic>cholerae</italic> O1-antigen MBC responses following BivWC vaccination. Adults in St. Marc, Haiti, received 2 doses of the BivWC vaccine, Shanchol, two weeks apart. Participants were invited to return at days 7, 21, 44, 90, 180 and 360 after the initial vaccination. Serum antibody and MBC responses were assessed at each time-point before and following vaccination. We observed that vaccination with BivWC resulted in significant O-antigen specific MBC responses to both Ogawa and Inaba serotypes that were detected by day 21 and remained significantly elevated over baseline for up to 12 months following vaccination. The BivWC oral cholera vaccine induces durable MBC responses to the <italic>V</italic>. <italic>cholerae</italic> O1-antigen. This suggests that long-term protection observed following vaccination with BivWC could be mediated or maintained by MBC responses.</p>
</abstract>
<abstract abstract-type="summary">
<title>Author summary</title>
<p>Oral cholera vaccines are being increasingly used throughout the world as a key component of cholera prevention programs. While several recent studies suggest oral cholera vaccines may provide durable protection, the potential mechanism that generates this long lasting immune memory and protection are unknown. Unlike antibody and antibody secreting cell responses, memory B cells are thought to be an important part of the immune responses because although these cells do not produce antibody, they are long lived and can be rapidly stimulated to produce antibodies upon re-exposure to infection. Previous studies have shown that memory B cell responses to the <italic>Vibrio cholerae</italic> O-antigen are associated with protection against cholera infection. In this study, we found that oral cholera vaccine generated long lasting antibody and memory B cell responses to the <italic>Vibrio cholerae</italic> O-antigen that remained elevated for 6 to 12 months. These findings show that oral cholera vaccination does induce a strong memory B cell response, which could play a role in the generation and maintenance of long-term protection following BivWC vaccination.</p>
</abstract>
<funding-group>
<award-group id="award001">
<funding-source>
<institution>American Society for Tropical Medicine and Hygeine</institution>
</funding-source>
<award-id>Centennial Award</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Falkard</surname>
<given-names>Brie</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award002">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000060</institution-id>
<institution>National Institute of Allergy and Infectious Diseases</institution>
</institution-wrap>
</funding-source>
<award-id>AI099243</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Harris</surname>
<given-names>Jason B.</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award003">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000060</institution-id>
<institution>National Institute of Allergy and Infectious Diseases</institution>
</institution-wrap>
</funding-source>
<award-id>AI103055</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Harris</surname>
<given-names>Jason B.</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award004">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000060</institution-id>
<institution>National Institute of Allergy and Infectious Diseases</institution>
</institution-wrap>
</funding-source>
<award-id>AI106878</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Ryan</surname>
<given-names>Edward T.</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award005">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000060</institution-id>
<institution>National Institute of Allergy and Infectious Diseases</institution>
</institution-wrap>
</funding-source>
<award-id>AI089721</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Charles</surname>
<given-names>Richelle C.</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award006">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000862</institution-id>
<institution>Doris Duke Charitable Foundation</institution>
</institution-wrap>
</funding-source>
<award-id>Clinical Research Fellows Program</award-id>
<principal-award-recipient>
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-5371-1354</contrib-id>
<name name-style="western">
<surname>Matias</surname>
<given-names>Wilfredo R.</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award007">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000867</institution-id>
<institution>Robert Wood Johnson Foundation</institution>
</institution-wrap>
</funding-source>
<award-id>72424</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Charles</surname>
<given-names>Richelle C.</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award008">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100006691</institution-id>
<institution>Harvard Medical School</institution>
</institution-wrap>
</funding-source>
<award-id>DICP Faculty Fellowship Award</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Charles</surname>
<given-names>Richelle C.</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award009">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100005294</institution-id>
<institution>Massachusetts General Hospital</institution>
</institution-wrap>
</funding-source>
<award-id>Transformative Scholars Award</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Charles</surname>
<given-names>Richelle C.</given-names>
</name>
</principal-award-recipient>
</award-group>
<funding-statement>This work was supported by the National Institute of Allergy and Infectious Diseases, National Institutes of Health (<ext-link ext-link-type="uri" xlink:href="https://www.niaid.nih.gov/" xlink:type="simple">https://www.niaid.nih.gov/</ext-link>) (AI099243 to JBH, LCI, MFF; AI103055 to JBH, FQ; AI106878 to ETR, FQ; K08 AI089721 to RCC) and by the Intramural Research Program of the National Institutes of Health, NIDDK; Doris Duke Charitable Foundation International Clinical Research Fellows Program (<ext-link ext-link-type="uri" xlink:href="http://www.ddcf.org/" xlink:type="simple">http://www.ddcf.org/</ext-link> - WRM); the Robert Wood Johnson Foundation Harold Amos Medical Faculty Development Program (<ext-link ext-link-type="uri" xlink:href="http://www.amfdp.org/" xlink:type="simple">http://www.amfdp.org/</ext-link> - 72424 to RCC); the Harvard Medical School DICP Faculty Fellowship Award (<ext-link ext-link-type="uri" xlink:href="https://mfdp.med.harvard.edu/DICP_Faculty_Fellowship" xlink:type="simple">https://mfdp.med.harvard.edu/DICP_Faculty_Fellowship</ext-link> - RCC); the Massachusetts General Hospital Department of Medicine Transformative Scholars Award (<ext-link ext-link-type="uri" xlink:href="https://giving.massgeneral.org/medicine/transformative-scholars/" xlink:type="simple">https://giving.massgeneral.org/medicine/transformative-scholars/</ext-link> RCC); and a Centennial Award from the American Society for Tropical Medicine (<ext-link ext-link-type="uri" xlink:href="http://www.astmh.org/awards-fellowships-medals/awards-and-honors/centennial-travel-award" xlink:type="simple">http://www.astmh.org/awards-fellowships-medals/awards-and-honors/centennial-travel-award</ext-link> - BF). The funders had no role in study design, data collection and analysis, decision to public or preparation of the manuscript.</funding-statement>
</funding-group>
<counts>
<fig-count count="5"/>
<table-count count="2"/>
<page-count count="14"/>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>PLOS Publication Stage</meta-name>
<meta-value>vor-update-to-uncorrected-proof</meta-value>
</custom-meta>
<custom-meta>
<meta-name>Publication Update</meta-name>
<meta-value>2019-02-12</meta-value>
</custom-meta>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>All of the data is contained with the submitted manuscript and its figures.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec001" sec-type="intro">
<title>Introduction</title>
<p><italic>Vibrio cholerae</italic> is the causative agent of cholera and responsible for approximately 1.3 to 4 million cases of diarrhea and 21,000 to 143,000 deaths, annually[<xref ref-type="bibr" rid="pntd.0007057.ref001">1</xref>]. Large cholera epidemics occur frequently and are even more devastating when <italic>V</italic>. <italic>cholerae</italic> is introduced into an immunologically naïve population. Oral cholera vaccines (OCVs) are an essential component of the World Health Organization (WHO) strategic roadmap that aims to reduce 90% of cholera deaths by 2030[<xref ref-type="bibr" rid="pntd.0007057.ref002">2</xref>].</p>
<p>There are three currently WHO prequalified, commercially available killed whole-cell OCVs. WC-rBS (currently manufactured as Dukoral by Valneva) is a whole-cell vaccine that consists of heat and formalin inactivated <italic>V</italic>. <italic>cholerae</italic> O1 derived from both the Inaba and Ogawa serotypes and includes recombinant cholera toxin B subunit (CTB). A second bivalent vaccine, BivWC (currently manufactured as Shanchol by Shantha Biotechnics), contains <italic>V</italic>. <italic>cholerae</italic> serogroups O1 and O139 but lacks the additional CTB antigen. The third vaccine, Euvichol by EuBiologics, is considered to be a bioequivalent to Shanchol. In 2013, WHO created a stockpile of the BivWC vaccine to respond to cholera outbreaks worldwide and it has been increasingly utilized to reduce the burden of epidemic cholera[<xref ref-type="bibr" rid="pntd.0007057.ref003">3</xref>,<xref ref-type="bibr" rid="pntd.0007057.ref004">4</xref>].</p>
<p>Despite the increasing use of BivWC, there are still important questions about its immunogenicity, especially in areas outside the historically cholera-endemic areas of South Asia. While natural infection with <italic>V</italic>. <italic>cholerae</italic> induces long-term memory B cell (MBC) responses that are correlated with protection against <italic>V</italic>. <italic>cholerae</italic> infection[<xref ref-type="bibr" rid="pntd.0007057.ref005">5</xref>], the WC-rBS vaccine does not appear to induce significant MBC responses, despite a similar initial plasma antibody response[<xref ref-type="bibr" rid="pntd.0007057.ref006">6</xref>,<xref ref-type="bibr" rid="pntd.0007057.ref007">7</xref>]. This finding might account for the relatively short-lived protection afforded by the WC-rBS vaccine[<xref ref-type="bibr" rid="pntd.0007057.ref008">8</xref>]. In contrast, data from recent clinical trials and epidemiologic studies demonstrate that BivWC vaccine likely affords longer lasting protection[<xref ref-type="bibr" rid="pntd.0007057.ref009">9</xref>]. However, there are no data currently available on whether the BivWC vaccine induces a MBC response.</p>
<p>To address this knowledge gap, we evaluated the development of cholera-specific MBC and serologic responses over the period of one year following BivWC vaccination in Haitian adults. The primary objective was to determine whether the BivWC vaccine, administered according to the currently recommended two-dose regimen 14 days apart, induced a MBC response in adults living in a cholera endemic region.</p>
</sec>
<sec id="sec002" sec-type="materials|methods">
<title>Methods</title>
<sec id="sec003">
<title>Ethics statement</title>
<p>The study was a conducted in the Saint Nicolas Hospital in St. Marc, Haiti, an urban center in the Artibonite Department. We invited healthy adults, ages 18–60 years presenting to the Saint Nicolas Hospital outpatient clinic between 2015–2016, to participate in this study. All participants provided a written informed consent prior to enrollment in the study. The protocol was reviewed and approved by the institutional review board of Partners HealthCare in Boston, Massachusetts and the Haitian National Bioethics Committee in Port-au-Prince, Haiti. All enrolled study participants were adults, over the age of 18 years. We excluded individuals if they had previously received OCV, were pregnant (by a urine test), or had an active gastrointestinal disorder within the 7 days prior to enrollment. We administered two doses of BivWC vaccine (Shanchol) 14 days apart to the study participants in accordance with manufacturer’s recommendations. We collected venous blood samples at day 0 (prior to vaccination), day 7 (7 days after the first dose of the vaccine), day 21 (7 days after the second vaccine dose), day 44, day 90, day 180 and day 360. We isolated peripheral blood mononuclear cells (PBMCs) by density gradient centrifugation and cryopreserved in liquid nitrogen. We also collected plasma from the processed blood after centrifugation and stored them frozen at ≥ -80°C.</p>
</sec>
<sec id="sec004">
<title>Vibriocidal antibody assay</title>
<p>We measured vibriocidal antibody titers at each time-point using guinea pig complement and <italic>V</italic>. <italic>cholerae</italic> O1 Ogawa PIC158 and Inaba PIC018 as the target organisms as previously described[<xref ref-type="bibr" rid="pntd.0007057.ref010">10</xref>]. Briefly, the serum was 2-fold serially diluted in a 96 well plate 11 times (until a final dilution of 1:10,240). Each sample dilution was run in duplicate on the same plate. Diluted bacteria and complement (final concentration 1:10) were added to each well prior to incubation on a shaker at 37°C for 1 hour (50 rev/min). Subsequently, 150μl of BHI media was added per well to grow bacteria strains for 2-4hrs at 37°C until it reached an optical density (O.D.) between 0.2 to 0.28. We used a monoclonal antibody (designated OSP-A2) that binds to the O-specific polysaccharide (OSP) moiety of LPS as a standard to monitor intra-assay variability between plates[<xref ref-type="bibr" rid="pntd.0007057.ref011">11</xref>]. The O.D.s of each sample were averaged between wells within the same plate and experiments were rejected and repeated, if we did not see 50% killing of <italic>V</italic>. <italic>cholerae</italic> with the concentration of 31.25 to 62.5ng/mL of the monoclonal antibody. All time-point samples from the same participant were run on the same plate to minimize assay variations. The vibriocidal titer was defined as reciprocal of the highest dilution resulting in &gt;50% reduction of the optical density of control wells without plasma.</p>
</sec>
<sec id="sec005">
<title>Detection of cholera-specific antigen antibody levels in plasma</title>
<p>We used a standard enzyme-linked immunosorbent assay (ELISA) to measure plasma IgA, IgG and IgM antibody responses to <italic>V</italic>. <italic>cholerae -</italic>OSP as described previously[<xref ref-type="bibr" rid="pntd.0007057.ref012">12</xref>,<xref ref-type="bibr" rid="pntd.0007057.ref013">13</xref>]. OSP was purified and conjugated to bovine serum albumin (BSA) as previously described[<xref ref-type="bibr" rid="pntd.0007057.ref014">14</xref>,<xref ref-type="bibr" rid="pntd.0007057.ref015">15</xref>]. We coated ELISA plates (MaxiSorp high affinity protein binding plates) with either <italic>V</italic>. <italic>cholerae</italic> O1 Ogawa or Inaba OSP conjugated to BSA (1 μg/mL) dissolved in 50mM carbonate buffer (pH 9.6). We then incubated plates with 100 μL of plasma (diluted in 1:50) and bound antibody was detected with horseradish peroxidase-conjugated goat anti-human IgA, IgG or IgM (dilution at 1:1000) and the color substrate, ABTS/H<sub>2</sub>O<sub>2</sub> (Sigma-Aldrich, St. Louis, MO). We measured absorbance values at 405 nm wavelength using kinetic readings (milliabsorbance/second) and SoftMax Pro software (version 5.3, Sunnyvale CA).</p>
</sec>
<sec id="sec006">
<title>Memory B cell (MBC) detection for IgG and IgA</title>
<p>We measured MBC responses to <italic>V</italic>. <italic>cholerae-</italic>specific antigens as previously described[<xref ref-type="bibr" rid="pntd.0007057.ref016">16</xref>]. Briefly, we thawed and rested PBMCs overnight at 37°C, 5% CO<sub>2</sub>, and then resuspended to a concentration of 5 x10<sup>5</sup> PBMC/ well in 24-well cell culture plates (BD Biosciences, San Jose, CA). We then added a mixture of mitogens, optimized to stimulate antigen-independent proliferation and differentiation of memory B cells into antibody-secreting cells (ASCs) to some wells, while media without mitogens was added to ‘no stimulation’ control wells. The mitogens were added to a final concentration of 3 μg of CpG (Toll-like receptor 9 agonist) oligonucleotide/mL (Operon, Huntsville, AL), 20 ng of B-cell activating factor (BAFF)/ mL (PeproTech, Rocky Hill, NJ) and 5 ng of cytokine interleukin-15 per mL (PeproTech, Rocky Hill, NJ) [<xref ref-type="bibr" rid="pntd.0007057.ref017">17</xref>]. We then incubated the cells at 37°C with 5% CO<sub>2</sub> for 6 days. For the enzyme-linked immunosorbent spot (ELISPOT) assay, we coated nitrocellulose-bottom plates (Mashan-4550; Millipore, Bedford, MA) with 100μl of <italic>V</italic>. <italic>cholerae</italic> O1 Ogawa or Inaba, OSP conjugated to BSA, at a concentration of 10 μg/ml in 1x Phosphate-buffered saline (PBS). We also coated plates with 100μl of affinity-purified goat anti-human IgG F(ab)<sub>2</sub> (Jackson Immunology Research, West Grove, PA) at a concentration of 5 μg/mL in PBS (pH 7.4), CtxB at 2.5 μg/mL (Sigma Aldrich) and keyhole limpet hemocyanin (KLH, Pierce Biotechnology, Rockford, IL, 2.5 μg/mL). We used KLH as a negative control to detect non-antigen specific responses, and CtxB to assess for MBC responses that might result from exposure to natural <italic>V</italic>. <italic>cholerae</italic> infection. We used 20% of harvested PBMCs from each well to measure total IgG and IgA MBC and 80% to measure antigen-specific IgG and IgA MBCs. To detect MBCs, we used a dual color assay with horseradish peroxidase-conjugated mouse anti-human IgA (Hybridoma Reagent Laboratory, Baltimore, MA) and alkaline phosphatase-conjugated mouse anti-human IgG (Southern Biotech, Birmingham, AL). We then developed the plates with 5-bromo-4-choloro-3-indolylphosphate-nitroblue tetrazolium (BCIP/NBT, Sigma-Aldrich) and 3-amino-9-ethylcarbazole (AEC, Sigma Aldrich). Two individuals using a stereomicroscope independently quantified MBCs and the average of these determined the final number of antigen-specific and total IgG and IgA expressing MBCs per sample.</p>
<p>As in previous studies, we excluded from our analysis samples that did not demonstrate sufficient stimulation by mitogens or a high number of negative control spots[<xref ref-type="bibr" rid="pntd.0007057.ref006">6</xref>,<xref ref-type="bibr" rid="pntd.0007057.ref016">16</xref>]. Specifically, samples which did not demonstrate a ≥ 4-fold increase in total IgG or IgA antibody secreting cells after stimulation, or those in which the KLH wells contained &gt; 3 spots were excluded from the analysis. A responder was defined as an individual with detectable MBC after vaccination with no prior MBCs on day 0 or an individual with detectable MBCs on day 0 and a 50% increase of MBCs after vaccination. The percentage of responders is the combination of both these groups over the total number of vaccinees.</p>
</sec>
<sec id="sec007">
<title>Detection of IgM antibodies from memory B cell supernatants</title>
<p>Because measuring IgM MBC responses by ELISPOT results in a high number of non-specific spots in both <italic>V</italic>. <italic>cholerae</italic> and KLH wells and because of the limited number of available PBMCs, we instead measured <italic>V</italic>. <italic>cholerae</italic> O1 antigen-specific IgM antibodies in MBC supernatants by ELISA as described previously[<xref ref-type="bibr" rid="pntd.0007057.ref018">18</xref>]. We collected MBC cell culture supernatants after 6 days of incubation from both stimulated and un-stimulated cultures and added a cocktail of protease inhibitors before freezing at -80°C. We measured the OSP-specific IgM responses in the supernatants using the ELISA method described above for plasma. In addition, we measured the total IgM in each supernatant to normalize the OSP-specific IgM antibody level to the total IgM concentration per well.</p>
</sec>
<sec id="sec008">
<title>Statistical analysis</title>
<p>We performed statistical analyses using STATA Version 14 (StataCorp, LP, College Station, TX) and Graph-Pad Prism (Graph Pad Software, Inc., La Jolla, CA). We expressed vibriocidal titers as geometric mean titers (GMT) with 95% confidence intervals. Antibody levels were expressed as a mean of ELISA units with standard error; and antigen-specific MBC responses were presented as a percentage of the total number of IgG or IgA MBCs. We used a paired <italic>t</italic>-test to compare responses between baseline (pre-vaccination) and subsequent time points.</p>
</sec>
</sec>
<sec id="sec009" sec-type="results">
<title>Results</title>
<sec id="sec010">
<title>Study enrollment and participation</title>
<p>A representation of the enrollment and follow-up of the study participants is shown in <xref ref-type="fig" rid="pntd.0007057.g001">Fig 1</xref>. The participants were enrolled in three separate cohorts, and the first set of 24 participants did not have a day 44 visit which is the reason for the lower number of participants evaluated at this time point. 93% of the participants returned for a minimum of 1 follow-up point, therefore a total of 68 individuals were included in subsequent statistical comparisons. Demographic features of the study participants are listed in <xref ref-type="table" rid="pntd.0007057.t001">Table 1</xref>. No adverse events were reported related to vaccination of the study participants.</p>
<fig id="pntd.0007057.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pntd.0007057.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Enrollment, vaccination and follow-up of study participants.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pntd.0007057.g001" xlink:type="simple"/>
</fig>
<table-wrap id="pntd.0007057.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pntd.0007057.t001</object-id>
<label>Table 1</label> <caption><title>Participant demographics.</title></caption>
<alternatives>
<graphic id="pntd.0007057.t001g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pntd.0007057.t001" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left">Characteristics</th>
<th align="left">Total<break/><italic>N = 73</italic></th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="2">Age (years)</td>
</tr>
<tr>
<td align="left">Mean</td>
<td align="left">29</td>
</tr>
<tr>
<td align="left">Range, S. D.</td>
<td align="left">18–58, 9.5</td>
</tr>
<tr>
<td align="left" colspan="2">Gender (%)</td>
</tr>
<tr>
<td align="left">Females</td>
<td align="left">32 (44)</td>
</tr>
<tr>
<td align="left">Males</td>
<td align="left">41 (56)</td>
</tr>
<tr>
<td align="left" colspan="2">Blood Type (%)</td>
</tr>
<tr>
<td align="left">A</td>
<td align="left">17 (23)</td>
</tr>
<tr>
<td align="left">B</td>
<td align="left">12 (16)</td>
</tr>
<tr>
<td align="left">O</td>
<td align="left">35 (48)</td>
</tr>
<tr>
<td align="left">AB</td>
<td align="left">9 (12)</td>
</tr>
<tr>
<td align="left" colspan="2">Vibriocidal Titer at Day 0 (%)</td>
</tr>
<tr>
<td align="left">Ogawa ≥ 80</td>
<td align="left">18 (25)</td>
</tr>
<tr>
<td align="left">Ogawa &lt; 80</td>
<td align="left">55 (75)</td>
</tr>
<tr>
<td align="left">Inaba ≥ 80</td>
<td align="left">7 (10)</td>
</tr>
<tr>
<td align="left">Inaba &lt; 80</td>
<td align="left">66 (90)</td>
</tr>
</tbody>
</table>
</alternatives>
</table-wrap>
</sec>
<sec id="sec011">
<title>Vibriocidal antibody responses</title>
<p>Vibriocidal antibody response is a measurement of the total amount of antibodies targeting the <italic>V</italic>. <italic>cholerae</italic> bacteria and is commonly used to determine the level of prior exposure within an individual. Vibriocidal antibody responses following vaccination are shown in <xref ref-type="fig" rid="pntd.0007057.g002">Fig 2</xref>, with seroconversion rates listed in <xref ref-type="table" rid="pntd.0007057.t002">Table 2</xref>. As expected, the baseline vibriocidal titers of the participants suggested a high level of previous exposure to <italic>V</italic>. <italic>cholerae</italic>; 18 of 73 (24.6%) had a vibriocidal titer ≥ 80 for Ogawa, while 7 of 73 (9.6%) had a vibriocidal titer ≥ 80 for Inaba. Consistent with our previous evaluations, over 80% of adults had a greater than fourfold increase in vibriocidal antibody titer against both serotypes following vaccination[<xref ref-type="bibr" rid="pntd.0007057.ref019">19</xref>,<xref ref-type="bibr" rid="pntd.0007057.ref020">20</xref>]. There is a significantly greater fold rise over baseline of Inaba vibriocidal antibody responses versus Ogawa on day 44, as measured by a paired <italic>t</italic>-test (p = 0.02).</p>
<fig id="pntd.0007057.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pntd.0007057.g002</object-id>
<label>Fig 2</label>
<caption>
<title>Vibriocidal responses.</title>
<p>Geometric mean titer (±SEM) of vibriocidal responses to <italic>V</italic>. <italic>cholerae</italic> O1 Ogawa (A) and Inaba (B). Statistically significant differences relative to baseline (Day 0) are indicated. (* = P&lt;0.05, ** = P&lt;0.01, *** = P&lt;0.001, **** = P&lt;0.0001). Seroconversion for vibriocidal is defined as ≥4-fold increase over baseline. Seroconversion for OSP is defined as ≥2-fold increase in kinetic ELISA. Participants were included if they positively seroconverted by either Day 7 or 21.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pntd.0007057.g002" xlink:type="simple"/>
</fig>
<table-wrap id="pntd.0007057.t002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pntd.0007057.t002</object-id>
<label>Table 2</label> <caption><title>Seroconversion rates.</title></caption>
<alternatives>
<graphic id="pntd.0007057.t002g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pntd.0007057.t002" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<tbody>
<tr>
<td align="left">Vibriocidal (Ogawa)</td>
<td align="left">83%</td>
</tr>
<tr>
<td align="left">Vibriocidal (Inaba)</td>
<td align="left">88%</td>
</tr>
<tr>
<td align="left">OSP IgG (Ogawa)</td>
<td align="left">51%</td>
</tr>
<tr>
<td align="left">OSP IgG (Inaba)</td>
<td align="left">44%</td>
</tr>
<tr>
<td align="left">OSP IgA (Ogawa)</td>
<td align="left">66%</td>
</tr>
<tr>
<td align="left">OSP IgA (Inaba)</td>
<td align="left">51%</td>
</tr>
</tbody>
</table>
</alternatives>
</table-wrap>
<p>The vibriocidal antibody response peaked on day 21 after 2 doses of vaccine and decreased in the subsequent time-points (day 44, 90, 180 and 360). However, in aggregate, the vibriocidal antibody titers remained significantly elevated over baseline titers even up to 1 year after vaccination for both the Inaba and Ogawa serotypes. Vibriocidal antibody titer geometric means and 95% confidence intervals for all time points are included in <xref ref-type="supplementary-material" rid="pntd.0007057.s001">S1 Table</xref>. A small number of participants (2 for Ogawa and 1 for Inaba) also had a fourfold or greater increase in vibriocidal titers by day 360 over day 180 suggesting possible re-exposure to <italic>V</italic>. <italic>cholerae</italic> during this period.</p>
</sec>
<sec id="sec012">
<title><italic>V</italic>. <italic>cholerae</italic>-O-polysaccharide specific antibody responses</title>
<p>O-specific polysaccharide (OSP) is the major antigen of immune responses that correlate to protection in <italic>V</italic>. <italic>cholerae</italic> infections. We determined antibody responses to the <italic>V</italic>. <italic>cholerae</italic> OSP antigen after each dose of BivWC vaccination and until day 360 (<xref ref-type="fig" rid="pntd.0007057.g003">Fig 3</xref>). We observed a robust response increase in Ogawa-OSP IgG and remained significantly elevated over baseline up to a year after vaccination. In contrast, mean IgM responses peaked on day 21, while IgA responses peaked on day 7; and there was no clear evidence of a sustained increase in circulating IgM or IgA OSP specific antibodies beyond day 44. Similar to the vibriocidal responses, we observed an increase in responses on day 360 relative to day 180 raising the possibility of re-exposure to <italic>V</italic>. <italic>cholerae</italic> during this period.</p>
<fig id="pntd.0007057.g003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pntd.0007057.g003</object-id>
<label>Fig 3</label>
<caption>
<title>OSP-specific responses.</title>
<p>Mean plasma antibody IgG (A), IgA (B) and IgM (C) OSP-specific responses to <italic>V</italic>. <italic>cholerae</italic> O1 Ogawa and Inaba. Statistically significant differences relative to baseline (Day 0) are indicated. (* = P&lt;0.05, ** = P&lt;0.01, *** = P&lt;0.001, **** = P&lt;0.0001).</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pntd.0007057.g003" xlink:type="simple"/>
</fig>
<p>We also performed an additional analysis, excluding a subset of individuals with evidence of recent prior exposure to <italic>V</italic>. <italic>cholerae</italic> (those individuals who had a day 0 vibriocidal titer &gt;80). Among this subset antibody responses remained significantly elevated over baseline within the same individual. However, vaccinees with serologic evidence of recent past exposure had a significantly increased rapid Ogawa-IgG antibody response compared to individuals without evidence of prior exposure after the first vaccine dose on day 7 (p = 0.04).</p>
<p>We also consistently observed a lower antibody response targeting Inaba-OSP compared to Ogawa-OSP for the IgG isotype, by a paired <italic>t</italic>-test analysis of fold-rise antibody responses on days 21, 44, 90 and 180 (p-values of 0.02, 0.02, 0.019 and 0.003, respectively). Whereas fold-rise of IgA antibodies targeting Inaba-OSP is lower than Ogawa-OSP on day 7 (p = 0.0004). However, the differences between Ogawa and Inaba antibody increases were no longer significant when removing individuals with evidence of previous exposure.</p>
</sec>
<sec id="sec013">
<title>Memory B cell responses</title>
<p>We measured the development of MBC responses in individuals to determine whether the BivWC vaccine is capable of stimulating these memory responses (<xref ref-type="fig" rid="pntd.0007057.g004">Fig 4</xref>). <italic>V</italic>. <italic>cholerae</italic> Ogawa-OSP antigen-specific MBCs demonstrated the most robust increase over baseline. The majority of vaccinees had a <italic>V</italic>. <italic>cholerae</italic> Ogawa-OSP IgG MBC response, with 67% demonstrating a response at day 21 and 64% demonstrating a response at day 44. In aggregate, these responses remained significantly elevated over baseline at 12 months post vaccination, the latest time point assessed. <italic>V</italic>. <italic>cholerae</italic> Inaba-OSP specific IgG-MBCs were also significantly elevated up to 6 months after vaccination. We also observed an increase in the number of circulating <italic>V</italic>. <italic>cholerae</italic> OSP specific IgA MBCs to both the Inaba and Ogawa serotypes, though these responses were detected in the circulation for a shorter duration of time after vaccination. Again, most vaccinees had detectable Ogawa IgA MBC responses following vaccination with a 51% responder frequency at day 21 and 60% at day 44. In addition, <italic>V</italic>. <italic>cholerae</italic> Ogawa and Inaba-OSP IgM-MBC responses (<xref ref-type="fig" rid="pntd.0007057.g005">Fig 5</xref>), as measured by ELISA in cell culture supernatants, (see <xref ref-type="sec" rid="sec002">methods</xref> for more experimental rationale), were detected after vaccination. They were no longer elevated after day 90 for Ogawa and day 44 for Inaba.</p>
<fig id="pntd.0007057.g004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pntd.0007057.g004</object-id>
<label>Fig 4</label>
<caption>
<title>Memory B Cell OSP-specific responses.</title>
<p>Mean antigen-specific IgG (A) and IgA (B) memory B cell responses to Ogawa and Inaba OSP, as percentages of total memory B cells, with error bars representing standard error of the mean. Statistically significant differences relative to baseline (Day 0) are indicated. (* = P&lt;0.05, ** = P&lt;0.01, *** = P&lt;0.001, **** = P&lt;0.0001).</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pntd.0007057.g004" xlink:type="simple"/>
</fig>
<fig id="pntd.0007057.g005" position="float">
<object-id pub-id-type="doi">10.1371/journal.pntd.0007057.g005</object-id>
<label>Fig 5</label>
<caption>
<title>IgM Memory B Cell OSP-specific responses.</title>
<p>Mean antigen-specific IgM memory B cell responses to Ogawa (A) and Inaba (B) OSP determined from ELISA measurements of lymphocyte culture supernatant. Statistically significant differences relative to baseline (Day 0) are indicated. (* = P&lt;0.05, ** = P&lt;0.01, *** = P&lt;0.001, **** = P&lt;0.0001).</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pntd.0007057.g005" xlink:type="simple"/>
</fig>
<p>We performed multiple regression analyses between early vibriocidal titers and subsequent immune responses to determine whether vibriocidal titers would be predictive of later immunity. However, we did not find significant associations between vibriocidal titers at baseline, day 7 or day 21 to any of the subsequent immune responses we evaluated in this study.</p>
<p>To evaluate whether the generation of MBC responses over the study period may have occurred from exposure to <italic>V</italic>. <italic>cholerae</italic> infection, we evaluated MBCs to the CTB protein for all individuals, at all-time points measured. CTB MBC responses were detected in 13 samples; 4% of total samples. When these samples were excluded from the overall analysis, it did not change the significance of MBC responses to vaccination at any time point over baseline.</p>
<p>To address the impact of likely prior exposure on memory responses after vaccination, we also performed a subsequent analysis in which we removed the individuals with baseline vibriocidal titers of 80 and above (<xref ref-type="supplementary-material" rid="pntd.0007057.s003">S1</xref> and <xref ref-type="supplementary-material" rid="pntd.0007057.s004">S2</xref> Figs). <italic>V</italic>. <italic>cholerae</italic> Ogawa-IgG MBC responses remain significantly elevated on days 21, 44 and 90, but the increase in MBCs were no longer significant for the later time points, day 180 or 360. Similarly, <italic>V</italic>. <italic>cholerae</italic> Inaba-IgG MBC responses remain significantly elevated on days 21 and 44 but are no longer significantly elevated on days 90 and 180. However, these later time points have the lowest sample numbers and the analysis could be underpowered.</p>
</sec>
</sec>
<sec id="sec014" sec-type="conclusions">
<title>Discussion</title>
<p>We found that the BivWC vaccine administered using a standard two dose regimen in a cholera endemic area induced a robust MBC response to the <italic>V</italic>. <italic>cholerae</italic> O-specific polysaccharide (OSP) antigen. In addition, we found that levels of circulating Ogawa specific IgG MBC responses remained significantly increased through one year after vaccination. Our study demonstrated persistent increases in circulating vibriocidal antibody titers to both serotypes and OSP IgG antibody titers for at least one year following vaccination.</p>
<p>This is an important finding since OSP specific MBC responses appear to be an immunological indicator of long-term protective immunity against cholera. For example, following natural infection with <italic>V</italic>. <italic>cholerae</italic>, MBC responses remain detectable longer than other immunologic responses after a <italic>V</italic>. <italic>cholerae</italic> infection[<xref ref-type="bibr" rid="pntd.0007057.ref021">21</xref>]; and the presence of detectable circulating IgA or IgG OSP MBCs are predictive of protection against <italic>V</italic>. <italic>cholerae</italic> following infection[<xref ref-type="bibr" rid="pntd.0007057.ref005">5</xref>] or vaccination[<xref ref-type="bibr" rid="pntd.0007057.ref022">22</xref>], even in exposed individuals without persistently elevated levels of circulating vibriocidal antibodies[<xref ref-type="bibr" rid="pntd.0007057.ref005">5</xref>].</p>
<p>Our results differ from previous studies evaluating MBC responses to the WC-rBS vaccine [<xref ref-type="bibr" rid="pntd.0007057.ref006">6</xref>,<xref ref-type="bibr" rid="pntd.0007057.ref007">7</xref>,<xref ref-type="bibr" rid="pntd.0007057.ref013">13</xref>]. These studies did not demonstrate a significant OSP MBC responses to the WC-rBS vaccination [<xref ref-type="bibr" rid="pntd.0007057.ref006">6</xref>,<xref ref-type="bibr" rid="pntd.0007057.ref007">7</xref>,<xref ref-type="bibr" rid="pntd.0007057.ref013">13</xref>]. Interestingly, this difference in immunogenicity between OCVs appears to be consistent with data from both clinical trial and field effectiveness studies which demonstrate that the BivWC vaccine provides significantly longer lasting protection than the WC-rBS vaccine [<xref ref-type="bibr" rid="pntd.0007057.ref009">9</xref>]. This difference in immunologic outcomes may reflect that CTB is a potent immunomodulatory agent. In mice, administration of CTB was found to suppress systemic immune responses, specifically dendritic cell priming Th2 responses and allergic inflammation [<xref ref-type="bibr" rid="pntd.0007057.ref023">23</xref>,<xref ref-type="bibr" rid="pntd.0007057.ref024">24</xref>]. CTB administered on mucosal surfaces also induces Treg cells, which would dampen immunological responses [<xref ref-type="bibr" rid="pntd.0007057.ref025">25</xref>]. In this context, it is notable that the original trial of the precursor of the WC-rBS vaccine compared a whole cell formulation alone with a whole cell plus CTB formulation, and immunity following the CTB containing version waned more rapidly than it did for participants who were vaccinated with the whole cell only vaccine [<xref ref-type="bibr" rid="pntd.0007057.ref026">26</xref>,<xref ref-type="bibr" rid="pntd.0007057.ref027">27</xref>]. An alternate explanation for this difference is that it could be attributable to the antigen content of the WC-rBS vaccine versus the BivWC vaccine, as the LPS content of the BivWC vaccine is significantly greater[<xref ref-type="bibr" rid="pntd.0007057.ref028">28</xref>].</p>
<p>We also observed longer lasting IgG antibody and memory B cell responses to the Ogawa-OSP antigen compared to Inaba-OSP after vaccination. Given that the Ogawa serotype has predominated in Haiti since 2010, it is possible that higher levels of previous exposure may have primed the development of IgG MBC responses. In addition, we found shorter duration of IgG MBC responses when excluding individuals with high baseline vibriocidal titers, as a measurement of recent prior exposure. These findings suggest prior exposure may lead to increased immunogenicity and longer duration of memory responses after vaccination. Future studies should take into consideration previous exposure when evaluating or comparing the immunogenicity and effectiveness of OCVs in different settings.</p>
<p>In conclusion, our study demonstrates the stimulation of long lasting O-specific polysaccharide antigen antibody and MBC responses by the BivWC vaccine in Haitian adults. The persistence of these immune responses was longer than expected given what has been observed in previous studies of the WC-rBS vaccine. Because MBC responses have been associated with protective immunity in previous studies [<xref ref-type="bibr" rid="pntd.0007057.ref005">5</xref>,<xref ref-type="bibr" rid="pntd.0007057.ref022">22</xref>], these results might provide an immunologic marker and potential mechanistic basis for the longer term protection observed following BivWC vaccination in adults living in a cholera endemic area.</p>
</sec>
<sec id="sec015">
<title>Supporting information</title>
<supplementary-material id="pntd.0007057.s001" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pntd.0007057.s001" xlink:type="simple">
<label>S1 Table</label>
<caption>
<title>Geometric means and 95% confidence intervals.</title>
<p>Vibriocidal, antibody titer and Memory B cell geometric means and 95% confidence intervals for all time points. Units of the geometric mean and confidence interval correspond to (a) Vibriocidal titer (b) ELISA units detected in serum samples (c) percent of specific MBC cells per 1,000 total IgG or IgA cells (d) ELISA units detected in MBC culture supernatant.</p>
<p>(TIF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pntd.0007057.s002" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet" position="float" xlink:href="info:doi/10.1371/journal.pntd.0007057.s002" xlink:type="simple">
<label>S2 Table</label>
<caption>
<title>Immunological responses for individual vaccinees.</title>
<p>Vaccinees de-identified, by ID number, for the individual antibody and MBC responses at each time-point measured. Legends for each individual immune response specified on the 2<sup>nd</sup> tab of the spreadsheet.</p>
<p>(XLSX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pntd.0007057.s003" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pntd.0007057.s003" xlink:type="simple">
<label>S1 Fig</label>
<caption>
<title>Memory B Cell OSP-specific IgG responses stratified by prior exposure.</title>
<p>MBC responses stratified by vibriocidal titer on day 0; high prior exposure defined as 80 or above, low prior exposure as below 80. Mean antigen-specific IgG memory B cell responses to Ogawa and Inaba OSP, as percentages of total memory B cells, with error bars representing standard error of the mean. Statistically significant differences relative to baseline (Day 0) are indicated. (* = P&lt;0.05, ** = P&lt;0.01, *** = P&lt;0.001, **** = P&lt;0.0001). “N” refers to the number of samples per group.</p>
<p>(TIF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pntd.0007057.s004" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pntd.0007057.s004" xlink:type="simple">
<label>S2 Fig</label>
<caption>
<title>Memory B Cell OSP-specific IgA responses stratified by prior exposure.</title>
<p>MBC responses stratified by vibriocidal titer on day 0; high prior exposure defined as 80 or above, low prior exposure as below 80. Mean antigen-specific IgA memory B cell responses to Ogawa and Inaba OSP, as percentages of total memory B cells, with error bars representing standard error of the mean. Statistically significant differences relative to baseline (Day 0) are indicated. (* = P&lt;0.05, ** = P&lt;0.01, *** = P&lt;0.001, **** = P&lt;0.0001). “N” refers to the number of samples per group.</p>
<p>(TIF)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ack>
<p>We thank the study participants as well as the Zanmi Lasante study team at the Hôpital St. Nicholas, St. Marc, Haiti.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="pntd.0007057.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ali</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Lopez</surname> <given-names>AL</given-names></name>, <name name-style="western"><surname>You</surname> <given-names>YA</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>YE</given-names></name>, <name name-style="western"><surname>Sah</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Maskery</surname> <given-names>B</given-names></name>, <etal>et al</etal>. <article-title>The global burden of cholera</article-title>. <source>Bull World Health Organ</source>. <year>2012</year>;<volume>90</volume>: <fpage>209</fpage>–<lpage>218A</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2471/BLT.11.093427" xlink:type="simple">10.2471/BLT.11.093427</ext-link></comment> <object-id pub-id-type="pmid">22461716</object-id></mixed-citation></ref>
<ref id="pntd.0007057.ref002"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><collab>Global Task Force on Cholera Control, World Health Organization (WHO)</collab>. <article-title>Declaration to Ending Cholera</article-title>. <year>2017</year>;: <fpage>1</fpage>–<lpage>2</lpage>.</mixed-citation></ref>
<ref id="pntd.0007057.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><collab>World Health Organization</collab>. <article-title>Deployments from the oral cholera vaccine stockpile, 2013–2017</article-title>. <source>Wkly Epidemiol Rec</source>. <year>2017</year>;<volume>92</volume>: <fpage>437</fpage>–<lpage>442</lpage>. <object-id pub-id-type="pmid">28799734</object-id></mixed-citation></ref>
<ref id="pntd.0007057.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Abubakar</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Azman</surname> <given-names>AS</given-names></name>, <name name-style="western"><surname>Rumunu</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Ciglenecki</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Helderman</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>West</surname> <given-names>H</given-names></name>, <etal>et al</etal>. <article-title>The First Use of the Global Oral Cholera Vaccine Emergency Stockpile: Lessons from South Sudan.</article-title> <source>PLoS Med</source>. <year>2015</year>;<volume>12</volume>: <fpage>e1001901</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pmed.1001901" xlink:type="simple">10.1371/journal.pmed.1001901</ext-link></comment> <object-id pub-id-type="pmid">26576044</object-id></mixed-citation></ref>
<ref id="pntd.0007057.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Patel</surname> <given-names>SM</given-names></name>, <name name-style="western"><surname>Rahman</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Mohasin</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Riyadh</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Leung</surname> <given-names>DT</given-names></name>, <name name-style="western"><surname>Alam</surname> <given-names>MM</given-names></name>, <etal>et al</etal>. <article-title>Memory B cell responses to Vibrio cholerae O1 lipopolysaccharide are associated with protection against infection from household contacts of patients with cholera in Bangladesh</article-title>. <source>Clin Vaccine Immunol</source>. <year>2012</year>;<volume>19</volume>: <fpage>842</fpage>–<lpage>848</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/CVI.00037-12" xlink:type="simple">10.1128/CVI.00037-12</ext-link></comment> <object-id pub-id-type="pmid">22518009</object-id></mixed-citation></ref>
<ref id="pntd.0007057.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Uddin</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Aktar</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Xu</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Johnson</surname> <given-names>RA</given-names></name>, <name name-style="western"><surname>Rahman</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Leung</surname> <given-names>DT</given-names></name>, <etal>et al</etal>. <article-title>Immune responses to O-specific polysaccharide and lipopolysaccharide of Vibrio cholerae O1 Ogawa in adult Bangladeshi recipients of an oral killed cholera vaccine and comparison to responses in patients with cholera</article-title>. <source>Am J Trop Med Hyg</source>. <year>2014</year>;<volume>90</volume>: <fpage>873</fpage>–<lpage>881</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.4269/ajtmh.13-0498" xlink:type="simple">10.4269/ajtmh.13-0498</ext-link></comment> <object-id pub-id-type="pmid">24686738</object-id></mixed-citation></ref>
<ref id="pntd.0007057.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Alam</surname> <given-names>MM</given-names></name>, <name name-style="western"><surname>Riyadh</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Fatema</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Rahman</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Akhtar</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Ahmed</surname> <given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Antigen-specific memory B-cell responses in Bangladeshi adults after one- or two-dose oral killed cholera vaccination and comparison with responses in patients with naturally acquired cholera</article-title>. <source>Clin Vaccine Immunol</source>. <year>2011</year>;<volume>18</volume>: <fpage>844</fpage>–<lpage>850</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/CVI.00562-10" xlink:type="simple">10.1128/CVI.00562-10</ext-link></comment> <object-id pub-id-type="pmid">21346055</object-id></mixed-citation></ref>
<ref id="pntd.0007057.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>van Loon</surname> <given-names>FP</given-names></name>, <name name-style="western"><surname>Clemens</surname> <given-names>JD</given-names></name>, <name name-style="western"><surname>Chakraborty</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Rao</surname> <given-names>MR</given-names></name>, <name name-style="western"><surname>Kay</surname> <given-names>BA</given-names></name>, <name name-style="western"><surname>Sack</surname> <given-names>DA</given-names></name>, <etal>et al</etal>. <article-title>Field trial of inactivated oral cholera vaccines in Bangladesh: results from 5 years of follow-up</article-title>. <source>Vaccine</source>. <year>1996</year>;<volume>14</volume>: <fpage>162</fpage>–<lpage>166</lpage>. <object-id pub-id-type="pmid">8852414</object-id></mixed-citation></ref>
<ref id="pntd.0007057.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kanungo</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Desai</surname> <given-names>SN</given-names></name>, <name name-style="western"><surname>Saha</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Nandy</surname> <given-names>RK</given-names></name>, <name name-style="western"><surname>Sinha</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>DR</given-names></name>, <etal>et al</etal>. <article-title>An Open Label Non-inferiority Trial Assessing Vibriocidal Response of a Killed Bivalent Oral Cholera Vaccine Regimen following a Five Year Interval in Kolkata, India</article-title>. <source>PLOS neglected tropical diseases</source>. <year>2015</year>;<volume>9</volume>: <fpage>e0003809</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pntd.0003809" xlink:type="simple">10.1371/journal.pntd.0003809</ext-link></comment> <object-id pub-id-type="pmid">26023778</object-id></mixed-citation></ref>
<ref id="pntd.0007057.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sayeed</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Bufano</surname> <given-names>MK</given-names></name>, <name name-style="western"><surname>Xu</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Eckhoff</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Charles</surname> <given-names>RC</given-names></name>, <name name-style="western"><surname>Alam</surname> <given-names>MM</given-names></name>, <etal>et al</etal>. <article-title>A Cholera Conjugate Vaccine Containing O-specific Polysaccharide (OSP) of V. cholerae O1 Inaba and Recombinant Fragment of Tetanus Toxin Heavy Chain (OSP:rTTHc) Induces Serum, Memory and Lamina Proprial Responses against OSP and Is Protective in Mice</article-title>. <source>PLOS neglected tropical diseases</source>. <year>2015</year>;<volume>9</volume>: <fpage>e0003881</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pntd.0003881" xlink:type="simple">10.1371/journal.pntd.0003881</ext-link></comment> <object-id pub-id-type="pmid">26154421</object-id></mixed-citation></ref>
<ref id="pntd.0007057.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kauffman</surname> <given-names>RC</given-names></name>, <name name-style="western"><surname>Bhuiyan</surname> <given-names>TR</given-names></name>, <name name-style="western"><surname>Nakajima</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Mayo-Smith</surname> <given-names>LM</given-names></name>, <name name-style="western"><surname>Rashu</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Hoq</surname> <given-names>MR</given-names></name>, <etal>et al</etal>. <article-title>Single-Cell Analysis of the Plasmablast Response to Vibrio cholerae Demonstrates Expansion of Cross-Reactive Memory B Cells.</article-title> <source>MBio</source>. <year>2016</year>;<volume>7</volume>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/mBio.02021-16" xlink:type="simple">10.1128/mBio.02021-16</ext-link></comment> <object-id pub-id-type="pmid">27999163</object-id></mixed-citation></ref>
<ref id="pntd.0007057.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Islam</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Hossain</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Kelly</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Mayo-Smith</surname> <given-names>LM</given-names></name>, <name name-style="western"><surname>Charles</surname> <given-names>RC</given-names></name>, <name name-style="western"><surname>Bhuiyan</surname> <given-names>TR</given-names></name>, <etal>et al</etal>. <article-title>Anti-O-specific polysaccharide (OSP) immune responses following vaccination with oral cholera vaccine CVD 103-HgR correlate with protection against cholera after infection with wild-type Vibrio cholerae O1 El Tor Inaba in North American volunteers</article-title>. <source>PLOS neglected tropical diseases</source>. <year>2018</year>;<volume>12</volume>: <fpage>e0006376</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pntd.0006376" xlink:type="simple">10.1371/journal.pntd.0006376</ext-link></comment> <object-id pub-id-type="pmid">29624592</object-id></mixed-citation></ref>
<ref id="pntd.0007057.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Alam</surname> <given-names>MM</given-names></name>, <name name-style="western"><surname>Leung</surname> <given-names>DT</given-names></name>, <name name-style="western"><surname>Akhtar</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Nazim</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Akter</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Uddin</surname> <given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Antibody avidity in humoral immune responses in Bangladeshi children and adults following administration of an oral killed cholera vaccine</article-title>. <source>Clin Vaccine Immunol</source>. <year>2013</year>;<volume>20</volume>: <fpage>1541</fpage>–<lpage>1548</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/CVI.00341-13" xlink:type="simple">10.1128/CVI.00341-13</ext-link></comment> <object-id pub-id-type="pmid">23925888</object-id></mixed-citation></ref>
<ref id="pntd.0007057.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Xu</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Alam</surname> <given-names>MM</given-names></name>, <name name-style="western"><surname>Kalsy</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Charles</surname> <given-names>RC</given-names></name>, <name name-style="western"><surname>Calderwood</surname> <given-names>SB</given-names></name>, <name name-style="western"><surname>Qadri</surname> <given-names>F</given-names></name>, <etal>et al</etal>. <article-title>Simple, direct conjugation of bacterial O-SP-core antigens to proteins: development of cholera conjugate vaccines</article-title>. <source>Bioconjug Chem</source>. <year>2011</year>;<volume>22</volume>: <fpage>2179</fpage>–<lpage>2185</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1021/bc2001984" xlink:type="simple">10.1021/bc2001984</ext-link></comment> <object-id pub-id-type="pmid">21899371</object-id></mixed-citation></ref>
<ref id="pntd.0007057.ref015"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Xu</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Kelly</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Vann</surname> <given-names>WF</given-names></name>, <name name-style="western"><surname>Qadri</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Ryan</surname> <given-names>ET</given-names></name>, <name name-style="western"><surname>Kovac</surname> <given-names>P</given-names></name>. <article-title>Conjugate Vaccines from Bacterial Antigens by Squaric Acid Chemistry: A Closer Look</article-title>. <source>Chembiochem</source>. <year>2017</year>;<volume>18</volume>: <fpage>799</fpage>–<lpage>815</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/cbic.201600699" xlink:type="simple">10.1002/cbic.201600699</ext-link></comment> <object-id pub-id-type="pmid">28182850</object-id></mixed-citation></ref>
<ref id="pntd.0007057.ref016"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Leung</surname> <given-names>DT</given-names></name>, <name name-style="western"><surname>Rahman</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Mohasin</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Patel</surname> <given-names>SM</given-names></name>, <name name-style="western"><surname>Aktar</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Khanam</surname> <given-names>F</given-names></name>, <etal>et al</etal>. <article-title>Memory B cell and other immune responses in children receiving two doses of an oral killed cholera vaccine compared to responses following natural cholera infection in Bangladesh</article-title>. <source>Clin Vaccine Immunol</source>. <year>2012</year>;<volume>19</volume>: <fpage>690</fpage>–<lpage>698</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/CVI.05615-11" xlink:type="simple">10.1128/CVI.05615-11</ext-link></comment> <object-id pub-id-type="pmid">22441386</object-id></mixed-citation></ref>
<ref id="pntd.0007057.ref017"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jahnmatz</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Kesa</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Netterlid</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Buisman</surname> <given-names>A-M</given-names></name>, <name name-style="western"><surname>Thorstensson</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Ahlborg</surname> <given-names>N</given-names></name>. <article-title>Optimization of a human IgG B-cell ELISpot assay for the analysis of vaccine-induced B-cell responses</article-title>. <source>J Immunol Methods</source>. <year>2013</year>;<volume>391</volume>: <fpage>50</fpage>–<lpage>59</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jim.2013.02.009" xlink:type="simple">10.1016/j.jim.2013.02.009</ext-link></comment> <object-id pub-id-type="pmid">23454005</object-id></mixed-citation></ref>
<ref id="pntd.0007057.ref018"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kendall</surname> <given-names>EA</given-names></name>, <name name-style="western"><surname>Tarique</surname> <given-names>AA</given-names></name>, <name name-style="western"><surname>Hossain</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Alam</surname> <given-names>MM</given-names></name>, <name name-style="western"><surname>Arifuzzaman</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Akhtar</surname> <given-names>N</given-names></name>, <etal>et al</etal>. <article-title>Development of immunoglobulin M memory to both a T-cell-independent and a T-cell-dependent antigen following infection with Vibrio cholerae O1 in Bangladesh</article-title>. <source>Infect Immun</source>. <year>2010</year>;<volume>78</volume>: <fpage>253</fpage>–<lpage>259</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/IAI.00868-09" xlink:type="simple">10.1128/IAI.00868-09</ext-link></comment> <object-id pub-id-type="pmid">19858296</object-id></mixed-citation></ref>
<ref id="pntd.0007057.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Matias</surname> <given-names>WR</given-names></name>, <name name-style="western"><surname>Falkard</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Charles</surname> <given-names>RC</given-names></name>, <name name-style="western"><surname>Mayo-Smith</surname> <given-names>LM</given-names></name>, <name name-style="western"><surname>Teng</surname> <given-names>JE</given-names></name>, <name name-style="western"><surname>Xu</surname> <given-names>P</given-names></name>, <etal>et al</etal>. <article-title>Antibody Secreting Cell Responses following Vaccination with Bivalent Oral Cholera Vaccine among Haitian Adults</article-title>. <source>PLOS neglected tropical diseases</source>. <year>2016</year>;<volume>10</volume>: <fpage>e0004753</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pntd.0004753" xlink:type="simple">10.1371/journal.pntd.0004753</ext-link></comment> <object-id pub-id-type="pmid">27308825</object-id></mixed-citation></ref>
<ref id="pntd.0007057.ref020"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Charles</surname> <given-names>RC</given-names></name>, <name name-style="western"><surname>Hilaire</surname> <given-names>IJ</given-names></name>, <name name-style="western"><surname>Mayo-Smith</surname> <given-names>LM</given-names></name>, <name name-style="western"><surname>Teng</surname> <given-names>JE</given-names></name>, <name name-style="western"><surname>Jerome</surname> <given-names>JG</given-names></name>, <name name-style="western"><surname>Franke</surname> <given-names>MF</given-names></name>, <etal>et al</etal>. <article-title>Immunogenicity of a killed bivalent (O1 and O139) whole cell oral cholera vaccine, Shanchol, in Haiti.</article-title> <source>PLOS neglected tropical diseases</source>. <year>2014</year>;<volume>8</volume>: <fpage>e2828</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pntd.0002828" xlink:type="simple">10.1371/journal.pntd.0002828</ext-link></comment> <object-id pub-id-type="pmid">24786645</object-id></mixed-citation></ref>
<ref id="pntd.0007057.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Harris</surname> <given-names>AM</given-names></name>, <name name-style="western"><surname>Bhuiyan</surname> <given-names>MS</given-names></name>, <name name-style="western"><surname>Chowdhury</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Khan</surname> <given-names>AI</given-names></name>, <name name-style="western"><surname>Hossain</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Kendall</surname> <given-names>EA</given-names></name>, <etal>et al</etal>. <article-title>Antigen-specific memory B-cell responses to Vibrio cholerae O1 infection in Bangladesh</article-title>. <source>Infect Immun</source>. <year>2009</year>;<volume>77</volume>: <fpage>3850</fpage>–<lpage>3856</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/IAI.00369-09" xlink:type="simple">10.1128/IAI.00369-09</ext-link></comment> <object-id pub-id-type="pmid">19528207</object-id></mixed-citation></ref>
<ref id="pntd.0007057.ref022"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Haney</surname> <given-names>DJ</given-names></name>, <name name-style="western"><surname>Lock</surname> <given-names>MD</given-names></name>, <name name-style="western"><surname>Gurwith</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Simon</surname> <given-names>JK</given-names></name>, <name name-style="western"><surname>Ishioka</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Cohen</surname> <given-names>MB</given-names></name>, <etal>et al</etal>. <article-title>Lipopolysaccharide-specific memory B cell responses to an attenuated live cholera vaccine are associated with protection against Vibrio cholerae infection</article-title>. <source>Vaccine</source>. <year>2018</year>;<volume>36</volume>: <fpage>2768</fpage>–<lpage>2773</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.vaccine.2018.04.011" xlink:type="simple">10.1016/j.vaccine.2018.04.011</ext-link></comment> <object-id pub-id-type="pmid">29655627</object-id></mixed-citation></ref>
<ref id="pntd.0007057.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sun</surname> <given-names>J-B</given-names></name>, <name name-style="western"><surname>Holmgren</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Czerkinsky</surname> <given-names>C</given-names></name>. <article-title>Cholera toxin B subunit: an efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>1994</year>;<volume>91</volume>: <fpage>10795</fpage>–<lpage>10799</lpage>. <object-id pub-id-type="pmid">7526379</object-id></mixed-citation></ref>
<ref id="pntd.0007057.ref024"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Smits</surname> <given-names>HH</given-names></name>, <name name-style="western"><surname>Gloudemans</surname> <given-names>AK</given-names></name>, <name name-style="western"><surname>van Nimwegen</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Willart</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Soullié</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Muskens</surname> <given-names>F</given-names></name>, <etal>et al</etal>. <article-title>Cholera toxin B suppresses allergic inflammation through induction of secretory IgA</article-title>. <source>Mucosal Immunology</source>. <year>2009</year>;<volume>2</volume>: <fpage>331</fpage>–<lpage>339</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/mi.2009.16" xlink:type="simple">10.1038/mi.2009.16</ext-link></comment> <object-id pub-id-type="pmid">19404246</object-id></mixed-citation></ref>
<ref id="pntd.0007057.ref025"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sun</surname> <given-names>J-B</given-names></name>, <name name-style="western"><surname>Cuburu</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Blomquist</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>B-L</given-names></name>, <name name-style="western"><surname>Czerkinsky</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Holmgren</surname> <given-names>J</given-names></name>. <article-title>Sublingual tolerance induction with antigen conjugated to cholera toxin B subunit induces Foxp3+CD25+CD4+ regulatory T cells and suppresses delayed-type hypersensitivity reactions</article-title>. <source>Scand J Immunol</source>. <year>2006</year>;<volume>64</volume>: <fpage>251</fpage>–<lpage>259</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1365-3083.2006.01823.x" xlink:type="simple">10.1111/j.1365-3083.2006.01823.x</ext-link></comment> <object-id pub-id-type="pmid">16918694</object-id></mixed-citation></ref>
<ref id="pntd.0007057.ref026"><label>26</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Clemens</surname> <given-names>JD</given-names></name>, <name name-style="western"><surname>Harris</surname> <given-names>JR</given-names></name>, <name name-style="western"><surname>Sack</surname> <given-names>DA</given-names></name>, <name name-style="western"><surname>Chakraborty</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Ahmed</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Stanton</surname> <given-names>BF</given-names></name>, <etal>et al</etal>. <article-title>Field trial of oral cholera vaccines in Bangladesh: results of one year of follow-up</article-title>. <source>J Infect Dis</source>. <year>1988</year>;<volume>158</volume>: <fpage>60</fpage>–<lpage>69</lpage>. <object-id pub-id-type="pmid">3392421</object-id></mixed-citation></ref>
<ref id="pntd.0007057.ref027"><label>27</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Clemens</surname> <given-names>JD</given-names></name>, <name name-style="western"><surname>Sack</surname> <given-names>DA</given-names></name>, <name name-style="western"><surname>Harris</surname> <given-names>JR</given-names></name>, <name name-style="western"><surname>Van Loon</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Chakraborty</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Ahmed</surname> <given-names>F</given-names></name>, <etal>et al</etal>. <article-title>Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up</article-title>. <source>The Lancet</source>. <year>1990</year>;<volume>335</volume>: <fpage>270</fpage>–<lpage>273</lpage>.</mixed-citation></ref>
<ref id="pntd.0007057.ref028"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Shin</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Desai</surname> <given-names>SN</given-names></name>, <name name-style="western"><surname>Sah</surname> <given-names>BK</given-names></name>, <name name-style="western"><surname>Clemens</surname> <given-names>JD</given-names></name>. <article-title>Oral vaccines against cholera</article-title>. <source>Clin Infect Dis</source>. <year>2011</year>;<volume>52</volume>: <fpage>1343</fpage>–<lpage>1349</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/cid/cir141" xlink:type="simple">10.1093/cid/cir141</ext-link></comment> <object-id pub-id-type="pmid">21498389</object-id></mixed-citation></ref>
</ref-list>
</back>
</article>